Bernard A. Fox, Co- founder, President, and CEO of UbiVac, shared Patrick Hwu’s, President and CEO at Moffitt Cancer Center, post on LinkedIn:
“Cancer’s Dark Matter was a topic or discussed in 4+ presentations at TIMO2026 in Brandenburg, Germany.
Bottom line – it is increasingly clear that cancer’s Dark Genome-derived (or Junk DNA- derived) non-canonical proteins, also termed cancer’s Dark Matter, play a role in cancer’s development and can serve as targets for destructive anti-cancer immune responses.
More background on role in cancer immunotherapy on Journal for ImmunoTherapy of Cancer.”
Proceed to the video attached to the post.
Title: Bright side of the dark genome: antigens for next-gen cancer vaccines
Authors: Xiao-Song Wang, Bernard A Fox
Read the Full Article.
Other articles about Bernard A. Fox on OncoDaily.